444 related articles for article (PubMed ID: 22056328)
1. Normal epidermal growth factor receptor signaling is dispensable for bone anabolic effects of parathyroid hormone.
Schneider MR; Dahlhoff M; Andrukhova O; Grill J; Glösmann M; Schüler C; Weber K; Wolf E; Erben RG
Bone; 2012 Jan; 50(1):237-44. PubMed ID: 22056328
[TBL] [Abstract][Full Text] [Related]
2. Unmasking the osteoinductive effects of a G-protein-coupled receptor (GPCR) kinase (GRK) inhibitor by treatment with PTH(1-34).
Wang L; Quarles LD; Spurney RF
J Bone Miner Res; 2004 Oct; 19(10):1661-70. PubMed ID: 15355561
[TBL] [Abstract][Full Text] [Related]
3. Sustained RANKL response to parathyroid hormone in oncostatin M receptor-deficient osteoblasts converts anabolic treatment to a catabolic effect in vivo.
Walker EC; Poulton IJ; McGregor NE; Ho PW; Allan EH; Quach JM; Martin TJ; Sims NA
J Bone Miner Res; 2012 Apr; 27(4):902-12. PubMed ID: 22190112
[TBL] [Abstract][Full Text] [Related]
4. Insulin-like growth factor I is required for the anabolic actions of parathyroid hormone on mouse bone.
Bikle DD; Sakata T; Leary C; Elalieh H; Ginzinger D; Rosen CJ; Beamer W; Majumdar S; Halloran BP
J Bone Miner Res; 2002 Sep; 17(9):1570-8. PubMed ID: 12211426
[TBL] [Abstract][Full Text] [Related]
5. Amphiregulin lacks an essential role for the bone anabolic action of parathyroid hormone.
Jay FF; Vaidya M; Porada SM; Andrukhova O; Schneider MR; Erben RG
Mol Cell Endocrinol; 2015 Dec; 417():158-65. PubMed ID: 26427650
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of the transcriptional factor Runx2 in osteoblasts abolishes the anabolic effect of parathyroid hormone in vivo.
Merciris D; Marty C; Collet C; de Vernejoul MC; Geoffroy V
Am J Pathol; 2007 May; 170(5):1676-85. PubMed ID: 17456773
[TBL] [Abstract][Full Text] [Related]
7. High cortical bone mass phenotype in betacellulin transgenic mice is EGFR dependent.
Schneider MR; Mayer-Roenne B; Dahlhoff M; Proell V; Weber K; Wolf E; Erben RG
J Bone Miner Res; 2009 Mar; 24(3):455-67. PubMed ID: 19049329
[TBL] [Abstract][Full Text] [Related]
8. The roles of parathyroid hormone in bone remodeling: prospects for novel therapeutics.
Lombardi G; Di Somma C; Rubino M; Faggiano A; Vuolo L; Guerra E; Contaldi P; Savastano S; Colao A
J Endocrinol Invest; 2011 Jul; 34(7 Suppl):18-22. PubMed ID: 21985975
[TBL] [Abstract][Full Text] [Related]
9. Anabolic actions of PTH (1-34): use of a novel tissue engineering model to investigate temporal effects on bone.
Pettway GJ; Schneider A; Koh AJ; Widjaja E; Morris MD; Meganck JA; Goldstein SA; McCauley LK
Bone; 2005 Jun; 36(6):959-70. PubMed ID: 15878317
[TBL] [Abstract][Full Text] [Related]
10. Low-dose PTH increases osteoblast activity via decreased Mef2c/Sost in senescent osteopenic mice.
Saidak Z; Le Henaff C; Azzi S; Marty C; Marie PJ
J Endocrinol; 2014 Oct; 223(1):25-33. PubMed ID: 25056116
[TBL] [Abstract][Full Text] [Related]
11. Targeted overexpression of G protein-coupled receptor kinase-2 in osteoblasts promotes bone loss.
Wang L; Liu S; Quarles LD; Spurney RF
Am J Physiol Endocrinol Metab; 2005 Apr; 288(4):E826-34. PubMed ID: 15585587
[TBL] [Abstract][Full Text] [Related]
12. Temporal expression of the anabolic action of PTH in cancellous bone of ovariectomized rats.
Meng XW; Liang XG; Birchman R; Wu DD; Dempster DW; Lindsay R; Shen V
J Bone Miner Res; 1996 Apr; 11(4):421-9. PubMed ID: 8992872
[TBL] [Abstract][Full Text] [Related]
13. Insulin receptor substrate-1 is required for bone anabolic function of parathyroid hormone in mice.
Yamaguchi M; Ogata N; Shinoda Y; Akune T; Kamekura S; Terauchi Y; Kadowaki T; Hoshi K; Chung UI; Nakamura K; Kawaguchi H
Endocrinology; 2005 Jun; 146(6):2620-8. PubMed ID: 15718274
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms for the bone anabolic effect of parathyroid hormone treatment in humans.
Aslan D; Andersen MD; Gede LB; de Franca TK; Jørgensen SR; Schwarz P; Jørgensen NR
Scand J Clin Lab Invest; 2012 Feb; 72(1):14-22. PubMed ID: 22085136
[TBL] [Abstract][Full Text] [Related]
15. Pregnancy-associated plasma protein-A modulates the anabolic effects of parathyroid hormone in mouse bone.
Clifton KB; Conover CA
Bone; 2015 Dec; 81():413-416. PubMed ID: 26297833
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous consequences of inhibiting EGF receptor signaling in vivo: normal hair follicle development, but retarded hair cycle induction and inhibition of adipocyte growth in Egfr(Wa5) mice.
Sugawara K; Schneider MR; Dahlhoff M; Kloepper JE; Paus R
J Dermatol Sci; 2010 Mar; 57(3):155-61. PubMed ID: 20060271
[TBL] [Abstract][Full Text] [Related]
17. Effects of cyclic vs. daily treatment with human parathyroid hormone (1-34) on murine bone structure and cellular activity.
Iida-Klein A; Lu SS; Cosman F; Lindsay R; Dempster DW
Bone; 2007 Feb; 40(2):391-8. PubMed ID: 17056311
[TBL] [Abstract][Full Text] [Related]
18. A novel flavonoid C-glucoside from Ulmus wallichiana preserves bone mineral density, microarchitecture and biomechanical properties in the presence of glucocorticoid by promoting osteoblast survival: a comparative study with human parathyroid hormone.
Khan MP; Mishra JS; Sharan K; Yadav M; Singh AK; Srivastava A; Kumar S; Bhaduaria S; Maurya R; Sanyal S; Chattopadhyay N
Phytomedicine; 2013 Nov; 20(14):1256-66. PubMed ID: 23928508
[TBL] [Abstract][Full Text] [Related]
19. Impaired bone anabolic response to parathyroid hormone in Fgf2-/- and Fgf2+/- mice.
Hurley MM; Okada Y; Xiao L; Tanaka Y; Ito M; Okimoto N; Nakamura T; Rosen CJ; Doetschman T; Coffin JD
Biochem Biophys Res Commun; 2006 Mar; 341(4):989-94. PubMed ID: 16455048
[TBL] [Abstract][Full Text] [Related]
20. Continuous parathyroid hormone and estrogen administration increases vertebral cancellous bone volume and cortical width in the estrogen-deficient rat.
Zhou H; Shen V; Dempster DW; Lindsay R
J Bone Miner Res; 2001 Jul; 16(7):1300-7. PubMed ID: 11450706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
